Nar Bahadur Katuwal
6PUBLICATIONS
9CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Nov 09, 2024
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer.Sa Deok Hong, Nar Bahadur Katuwal, Min Sil Kang
|Dec 09, 2023
PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal
|Oct 14, 2023
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer.Yeong Gyu Jeong, Nar Bahadur Katuwal, Min Sil Kang
|Jan 11, 2022
Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.Kamal Pandey, Nar Bahadur Katuwal, Nahee Park
|Jan 30, 2021
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.Jin Hur, Mithun Ghosh, Tae Heon Kim
|Jan 28, 2021
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.Kamal Pandey, Eunbyeol Lee, Nahee Park
Pageof 1
